Feb-06-23 09:55AM |
Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to TradeZacks Investment Research |
05:55AM |
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%The Motley Fool |
Feb-03-23 02:43AM |
4 Biotech Stocks Set to Outpace Q4 Earnings EstimatesZacks Investment Research |
Feb-01-23 01:03AM |
Analyst Initiates Coverage On This Peer Lagging Gene-Editing StockBenzinga |
10:00AM |
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023Benzinga |
Jan-27-23 01:28AM |
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2022 UpdateSeeking Alpha |
Jan-24-23 11:45AM |
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool |
11:00AM |
Expert Ratings for Intellia TherapeuticsBenzinga |
Jan-24-23 10:01AM |
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023Benzinga |
Jan-19-23 10:01AM |
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023Benzinga |
Jan-13-23 09:55AM |
Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?Zacks Investment Research |
Jan-12-23 12:15PM |
Prime Medicine 'Crispr 3.0' Vs. Crispr TherapeuticsSeeking Alpha |
Jan-11-23 07:30AM |
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaGlobeNewswire Inc. |
Jan-05-23 07:30AM |
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones GlobeNewswire Inc. |
Dec-30-22 10:07AM |
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)The Motley Fool |
Dec-02-22 07:59AM |
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For FridayBenzinga |
07:06AM |
Analyst Ratings for Intellia TherapeuticsBenzinga |
Nov-30-22 09:29AM |
Intellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc. |
04:37AM |
Intellia Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire Inc. |
Nov-15-22 06:53AM |
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%Benzinga |
Nov-12-22 04:30AM |
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingGlobeNewswire Inc. |
Nov-05-22 04:00AM |
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022GlobeNewswire Inc. |
Nov-03-22 01:27AM |
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/YZacks Investment Research |
07:30AM |
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc. |
Nov-02-22 12:51PM |
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag EstimatesZacks Investment Research |
12:30PM |
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 GuidanceZacks Investment Research |
Nov-01-22 10:27AM |
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022Benzinga |
Oct-31-22 07:30AM |
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific MeetingGlobeNewswire Inc. |
Oct-27-22 10:03AM |
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research |
07:30AM |
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company UpdatesGlobeNewswire Inc. |
Oct-24-22 05:21AM |
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research |
Oct-19-22 09:23AM |
3 Cathie Wood Stocks to Buy and Hold for 10 YearsThe Motley Fool |
03:10AM |
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 UpdateSeeking Alpha |
Oct-13-22 06:10AM |
Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?Zacks Investment Research |
Oct-11-22 10:06AM |
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022Benzinga |
09:18AM |
7 Analysts Have This to Say About Intellia TherapeuticsBenzinga |
Sep-22-22 05:49AM |
Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just BoughtThe Motley Fool |
Sep-21-22 10:04AM |
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022Benzinga |
Sep-20-22 05:55AM |
Cathie Wood Is Loading Up on These 3 Stocks: Should You?The Motley Fool |
Sep-19-22 05:35AM |
"The Era of the Gene-Edited Human Is Here"The Motley Fool |
12:15PM |
Intellia (NTLA) Reports Positive Results for CRISPR CandidatesZacks Investment Research |
Sep-19-22 12:06PM |
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To KnowBenzinga |
10:15AM |
2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 YearsThe Motley Fool |
Sep-19-22 10:02AM |
What 4 Analyst Ratings Have To Say About Intellia TherapeuticsBenzinga |
07:19AM |
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedExBenzinga |
Sep-16-22 07:15AM |
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisGlobeNewswire Inc. |
07:00AM |
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)GlobeNewswire Inc. |
Sep-01-22 10:33AM |
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022Benzinga |
09:18AM |
Expert Ratings for Intellia TherapeuticsBenzinga |
Sep-01-22 09:13AM |
Where Intellia Therapeutics Stands With AnalystsBenzinga |